Disclosure MD has reported scientific advisory boards for Accerta, Bayer, Celgene, Gilead, Janssen, Novartis, Roche and Sandoz, speaker's honoraria from Bayer, Celgene, Gilead, Janssen and Roche and research support from Celgene, Janssen, Mundipharma and Roche; GS has reported advisory boards or consulting for AbbVie, Autolus, Celgene, Genmab, Gilead, Epizyme, Janssen, Karyopharm, Kite, Merck, MorphoSys, Novartis, Roche, Servier and Takeda and educational events with AbbVie, Amgen, Celgene, Gilead, Janssen, Kite, MorphoSys, Novartis, Roche, Servier and Takeda; ML has reported consultancy, advisory boards, scientific meetings, institutional research support and contracts from AbbVie, Acerta, Amgen, Archigen, ADC Therapeutics, BeiGene, Celgene, Gilead, J&J, Jazz, Roche, Sandoz and Takeda and has received research grants from Celgene, J&J and BeiGene; KH has received research support from Roche; JFS has reported advisory boards for AbbVie, Celgene, Janssen, Roche, Acerta, Genentech, Gilead, Mei Pharma, MorphoSys, Sunesis and Takeda, speaker's bureau for AbbVie, Celgene and Roche and has received research funding from AbbVie, Celgene, Roche and Janssen; MJ has received research funding from Celgene, Roche, Gilead, AbbVie and Janssen and honoraria from Kite, Kyowa-Kirin and Acerta; MG, SR and SHT have declared no conflicts of interest.